Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...

Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Chugai, a Japanese company majority owned by Roche, has identified Gero’s platform as complementary to its own capabilities.